Skip to Main Content

Paper Details

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Clin Cancer Res
9
2023
Brain Metastases, CD4, CSF, Cell, HER2, HER2+, HER2-Positive Breast Cancer, Pneumocystis jirovecii, Pneumocystis jirovecii pneumonia, T-DM1, TMZ, Temozolomide, brain metastases, breast cancer, lymphopenia, neutropenia, parenchymal brain metastases, patient, patients, pentamidine, temozolomide, thrombocytopenia, women
Author NameAffiliation
Seth M SteinbergBiostatistics and Data Management Section Center for Cancer Research
Seth M SteinbergBiostatistics and Data Management Section Center for Cancer Research
Darryl NousomeCenter for Cancer Research Collaborative Bioinformatics Resource
Xiaolin WuLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research
Xiaolin WuLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research
Priscilla K BrastianosMassachusetts General Hospital, Harvard Cancer Center
Carey K AndersDuke Cancer Institute
Stanley LipkowitzCenter for Cancer Research
Stanley LipkowitzCenter for Cancer Research
Patricia S SteegCenter for Cancer Research
Patricia S SteegCenter for Cancer Research
  • 1 - 11

Datasets

Release 1.2